Annals of Thoracic Medicine
REVIEW ARTICLE
Year
: 2019  |  Volume : 14  |  Issue : 3  |  Page : 173--178

Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region


Arafat Hussein Tfayli, Ghina Bassam Fakhri, Majd Sassine Al Assaad 
 Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut, Beirut, Lebanon

Correspondence Address:
Dr. Arafat Hussein Tfayli
American University of Beirut Medical Center, Naef K. Basile Cancer Institute, 11-0236, Riad El Solh, 1107 2020, Beirut
Lebanon

Lung cancer remains a major cause of cancer mortality with a 5-year survival in advanced stages around 4%. Platinum-based chemotherapy was routinely used as the standard of care in patients with advanced nonsmall cell lung cancer, but it is being progressively replaced by targeted molecular therapy. One of the molecular aberrations harbored by lung adenocarcinoma is the epidermal growth factor receptor (EGFR). A large ethnic variation has been reported in the prevalence of EGFR mutations in patients with lung adenocarcinoma. Data regarding its prevalence from the Middle East area remains limited. This paper aims at reviewing the data available for the prevalence of this mutation in the Middle Eastern patient population and comparing it with other reported series.


How to cite this article:
Tfayli AH, Fakhri GB, Al Assaad MS. Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region.Ann Thorac Med 2019;14:173-178


How to cite this URL:
Tfayli AH, Fakhri GB, Al Assaad MS. Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. Ann Thorac Med [serial online] 2019 [cited 2019 Jul 23 ];14:173-178
Available from: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=173;epage=178;aulast=Tfayli;type=0